Liver
Cirrhosis
Cirrhosis is a condition involving liver health. This reference describes how selected options have been studied in relation to cirrhosis, rather than presenting them as treatments or medical advice.
A focused look at Cirrhosis and its place in liver health.
This list shows research findings, not treatments. Nothing here replaces medical care. If you have this condition, talk to a doctor.
What may help
None of these options has good evidence yet. Best evidence first.
1 option:1 not enough evidence
Strength TrainingpracticeNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit.
A pooled analysis found improved quality of life and 6MWT functional capacity with resistance and aerobic training in people with Cirrhosis, with no reported adverse events. The review cautioned that evidence was insufficient for Child-Pugh C.
Open the Strength Training page
The expert view shows every study, dose protocol and source.
What may help
Interventions recorded as helping with this condition1 listedThe best we have, but the evidence is still weak
- →PracticesStrength TrainingCertaintyLowSourceRCT
A pooled analysis found improved quality of life and 6MWT functional capacity with resistance and aerobic training in people with Cirrhosis, with no reported adverse events. The review cautioned that evidence was insufficient for Child-Pugh C.
Who was studied
- People with a condition
Open Strength TrainingStudy result
Meta-analysis of 6 RCTs showing improved quality of life (CLDQ) and 6MWT functional capacity with resistance and aerobic training, with no reported adverse events; caution advised for Child-Pugh C due to insufficient evidence.
What to avoid
Interventions recorded as making it worseNothing in this library is currently recorded as making Cirrhosis worse. Coverage is partial, and absence here is not evidence of safety.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
Cirrhosis is a condition involving liver health. This reference describes how selected options have been studied in relation to cirrhosis, rather than presenting them as treatments or medical advice.
Evidence-backed options
BCAA and Curcumin are associated with cirrhosis research, but their evidence bases are different. BCAA has clinical evidence related to long-term oral supplementation, with potential effects on liver function and major complications in people with advanced liver disease. This provides a human context, although the overall support is limited and the description does not establish how quickly any change may appear.
Curcumin has been studied in animal studies rather than in a specified human population. In rats, it inhibited cirrhosis induced by thioacetamide and was associated with decreases in oxidative stress and hydroxyproline levels. These findings do not establish whether the same effects occur in people with cirrhosis.
Specific doses, treatment durations, and onset timings are not provided for either option, so the available findings cannot define a standard course or expected timeframe. The evidence also does not establish applicability across all causes or stages of cirrhosis. Anyone considering these options for a medical condition should discuss them with a clinician.
What to avoid
Sodium Bicarbonate is flagged because its substantial sodium load can worsen sodium retention in decompensated cirrhosis. This may contribute to ascites, edema, and dilutional hyponatremia, making sodium exposure an important consideration when these complications are present.
Drink Enough Water is not a universally appropriate instruction for people with cirrhosis and ascites. Fluid restriction may be required to prevent worsening fluid accumulation, so hydration guidance depends on the person’s clinical situation rather than a general goal of increasing water intake.
MCT Oil is flagged because advanced liver disease can impair the liver’s metabolism of MCTs. This may increase hepatic load and worsen liver function. These concerns are specific to the effects of cirrhosis on sodium handling, fluid balance, and liver metabolism; any use or avoidance decision should be reviewed with a clinician familiar with the person’s condition.